Shaji K. Kumar, MD

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. A look at clinical trial efficacy data on daratumumab plus bortezomib and venetoclax for multiple myeloma treatment.

Shaji Kumar, MD, discusses how risk assessments and new drug combinations could influence treatment of patients with newly diagnosed multiple myeloma.

Shaji K. Kumar, MD, addresses an important unanswered question that remains in the treatment landscape of newly diagnosed multiple myeloma, which is whether 3- or 4-drug regimens should be used in the frontline setting.

Shaji K. Kumar, MD, discusses how patients with multiple myeloma respond to different types of therapy.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the management of newly diagnosed patients with multiple myeloma.

Shaji K. Kumar, MD, discusses the results of a phase II trial of single agent MLN9708 in patients with relapsed multiple myeloma not refractory to bortezomib.